Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia.
Stull
Dawn Marie
DM
Department of Pharmacy, New York Presbyterian Hospital-New York Weill Cornell Center, New York, NY 10128, USA. dmstull@nyp.org
Bilmes
Robyn
R
Kim
Helen
H
Fichtl
Rick
R
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001831:Body Temperature; D004334:Drug Administration Schedule; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D009503:Neutropenia / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D013810:Therapeutic Equivalency; D017211:Treatment Failure
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000069585:Filgrastim